Want to see CCRN full AI Analyst Report?
Top Page
Cross Country Healthcare
(NASDAQ:CCRN)
Select Model
Select Model
Rating:60Neutral
Price Target:
$14.00
▲(64.90% Upside)
Action:Reiterated
Date:07/28/26
The score is primarily held back by weak operating performance (declining revenue, compressed margins, and TTM losses), despite support from a low-debt balance sheet and positive cash flow. Technicals are moderately constructive with the stock above key moving averages, and corporate events (take-private at $13.25) provide a clearer valuation anchor, though closing and litigation risks remain. Valuation is penalized due to negative earnings and no dividend yield data.
Positive Factors
Conservative Balance Sheet
Very low debt and near-zero debt-to-equity materially reduce refinancing and solvency risk, giving the company durable financial flexibility. That balance-sheet strength supports investment in operations or technology, absorbs cyclical staffing demand swings, and underpins long-term stability.
Negative Factors
Sustained Revenue Decline
A prolonged ~28% TTM revenue decline and margin compression indicate structural demand or competitive challenges. Persisting top-line shrinkage undermines operating leverage, hampers margins and returns, and must be reversed to restore durable profitability and justify reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low debt and near-zero debt-to-equity materially reduce refinancing and solvency risk, giving the company durable financial flexibility. That balance-sheet strength supports investment in operations or technology, absorbs cyclical staffing demand swings, and underpins long-term stability.
Read all positive factors
Cross Country Healthcare (CCRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$428.06M
Dividend YieldN/A
Average Volume (3M)398.73K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-20.37%
EPS Growth-479.68%
CountryUS
Employees1,106
SectorHealthcare
Sector Strength45
IndustryStaffing & Employment Services
Share Statistics
EPS (TTM)-3.05
Shares Outstanding32,306,484
10 Day Avg. Volume380,139
30 Day Avg. Volume398,728
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio6.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.25Price Target Upside56.07% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.1
Revenue Forecast (FY)$984.97M
Cross Country Healthcare Business Overview & Revenue Model
Company Description
Cross Country Healthcare, Inc. is a U.S.-based provider specializing in talent management and consultative advisory services for healthcare organizations. The company operates through two main divisions: Nurse and Allied Staffing, and Physician St...
How the Company Makes Money
Cross Country Healthcare makes money primarily by placing healthcare professionals with client facilities and charging those clients for the labor delivered. Its core revenue model is staffing: the company recruits, credentials, and deploys nurses...
Cross Country Healthcare Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: the company reported significant revenue declines and a large noncash impairment that pressured profitability in 2025, but it also emphasized a strong balance sheet (no debt, $109M cash), meaningful cost reductions, accelerating weekly production and strategic investments in proprietary technology (Intellify/Xperience) and AI. Management provided cautious near-term guidance (Q1 revenue $235M–$240M; adjusted EBITDA ~$4M–$5M) while outlining a credible path to recovery — targeting a >$1B revenue run-rate and 4%–5% adjusted EBITDA margin by year-end 2026 — backed by redeployed cost savings, headcount optimization, and growth in higher-margin segments (home-based and education). Given the material past declines and impairment but clear remediation plans, the tone is cautiously optimistic with balanced risks and opportunities.Positive Updates
Strong balance sheet and capital flexibility
Ended Q4 with $109 million in cash and no debt, enabling discretionary deployment of capital. Completed share repurchases (December: >800,000 shares for $6.8M; additional ~486,000 shares purchased in Q1). Generated $18M cash from operations in Q4 and $48M for the full year.
Negative Updates
Material revenue declines
Consolidated Q4 revenue $237M, down 5% sequentially and 24% year-over-year. Full year revenue $1.05B, down 22% YoY. The declines are largely attributable to normalization of contingent utilization across core Nurse and Allied businesses (notably Travel).
Read all updates
Q4-2025 Updates
Positive
Negative
Strong balance sheet and capital flexibility
Ended Q4 with $109 million in cash and no debt, enabling discretionary deployment of capital. Completed share repurchases (December: >800,000 shares for $6.8M; additional ~486,000 shares purchased in Q1). Generated $18M cash from operations in Q4 and $48M for the full year.
Read all positive updates
Company Guidance
Management guided Q1 2026 revenue of $235–$240 million, adjusted EBITDA of $4–$5 million (≈2% margin) and adjusted EPS of a loss of $0.04–$0.06 on ~31.5 million shares, assuming gross margin of 19.5%–20%, net interest income of $0.3 million, depreciation & amortization of $4 million, stock‑based compensation of $1.3 million, a tax provision of ~$0.4 million and a ~$2 million payroll‑tax headwind; they also reiterated a 2026 exit target of a revenue run‑rate north of $1.0 billion (Q4 revenue >$250 million) and an adjusted EBITDA margin of 4%–5%.Cross Country Healthcare Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00B | 1.05B | 1.34B | 2.02B | 2.80B | 1.68B |
| Gross Profit | 198.84M | 196.78M | 274.25M | 450.41M | 624.46M | 375.00M |
| EBITDA | -68.41M | -64.50M | 16.77M | 129.34M | 280.06M | 154.56M |
| Net Income | -98.63M | -94.85M | -14.56M | 72.63M | 185.98M | 132.00M |
Balance Sheet | ||||||
| Total Assets | 451.07M | 448.95M | 589.25M | 679.32M | 947.84M | 732.81M |
| Cash, Cash Equivalents and Short-Term Investments | 105.58M | 108.74M | 81.63M | 17.09M | 3.60M | 1.04M |
| Total Debt | 2.04M | 2.32M | 3.87M | 5.27M | 157.75M | 195.49M |
| Total Liabilities | 138.27M | 126.13M | 170.29M | 205.92M | 490.62M | 435.28M |
| Stockholders Equity | 312.81M | 322.82M | 418.96M | 473.39M | 457.22M | 297.53M |
Cash Flow | ||||||
| Free Cash Flow | 39.60M | 40.09M | 111.40M | 234.52M | 125.26M | -92.79M |
| Operating Cash Flow | 47.34M | 48.25M | 120.12M | 248.50M | 134.05M | -85.62M |
| Investing Cash Flow | -7.73M | -8.16M | -8.71M | -13.78M | -43.87M | -34.05M |
| Financing Cash Flow | -14.74M | -13.01M | -46.85M | -221.24M | -87.60M | 119.09M |
Cross Country Healthcare Technical Analysis
Positive
8.49
Price Trends
13.19
Positive
11.77
Positive
10.78
Positive
Market Momentum
0.05
Positive
75.26
Negative
57.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCRN, the sentiment is Positive. The current price of 8.49 is below the 20-day moving average (MA) of 13.24, below the 50-day MA of 13.19, and below the 200-day MA of 10.78, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 75.26 is Negative, neither overbought nor oversold. The STOCH value of 57.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCRN.
Cross Country Healthcare Risk Analysis
Cross Country Healthcare disclosed 33 risk factors in its most recent earnings report. Cross Country Healthcare reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cross Country Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.76B | 57.58 | 3.88% | ― | 56.69% | -15.92% | |
62 Neutral | $1.30B | -39.10 | -4.98% | ― | 19.87% | 79.93% | |
60 Neutral | $428.06M | -4.34 | -27.10% | ― | -20.37% | -479.68% | |
59 Neutral | $1.54B | -37.65 | -9.20% | ― | 14.13% | 62.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.53B | -4.04 | -146.01% | ― | -2.82% | -45.70% | |
42 Neutral | $393.42M | -1.23 | 20.91% | ― | -5.25% | ― |
* Healthcare Sector Average
CCRN
Cross Country Healthcare
13.25
0.15
1.15%
AMN
AMN Healthcare Services
32.80
15.58
90.48%
CYH
Community Health
2.95
0.49
19.92%
ASTH
Astrana Health
35.83
14.02
64.28%
INNV
InnovAge Holding
11.09
7.71
228.11%
AGL
Agilon Health
107.85
85.60
384.72%
Cross Country Healthcare Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Knox Lane Takes Cross Country Healthcare Private, Restructures
Positive
Jul 28, 2026
On July 21, 2026, growth-focused investment firm Knox Lane completed its acquisition of Cross Country Healthcare, taking the company private and repositioning it as a standalone technology-enabled healthcare workforce solutions provider with a con...
Delistings and Listing ChangesM&A TransactionsShareholder Meetings
Cross Country Healthcare Shareholders Approve Going-Private Merger
Neutral
Jul 17, 2026
On July 16, 2026, Cross Country Healthcare held a special meeting at which stockholders voted on proposals related to a planned merger with KL Criss Cross Intermediate, LLC and its subsidiary. The transaction will see the merger subsidiary combine...
Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Cross Country Healthcare Faces Challenges to Planned Merger
Negative
Jul 6, 2026
On June 15, 2026, Cross Country Healthcare filed a definitive proxy statement outlining a planned merger under which KL Criss Cross Merger Sub will merge into the company, leaving Cross Country as a wholly owned subsidiary of KL Criss Cross Interm...
Business Operations and StrategyM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Cross Country Healthcare Advances Toward KL Criss Cross Merger
Positive
Jun 23, 2026
Cross Country Healthcare said the Hart-Scott-Rodino antitrust waiting period for its planned merger with KL Criss Cross Intermediate and the sale of its locums business to All Star Healthcare Solutions expired at 11:59 p.m. ET on June 22, 2026, sa...
Business Operations and StrategyStock BuybackDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
Cross Country Healthcare Reports Q1 Loss Amid Privatization Deal
Negative
May 7, 2026
Cross Country Healthcare reported first-quarter 2026 results on May 7, 2026, with consolidated revenue of $241.1 million, down 18% year over year but up 2% sequentially, and a net loss attributable to common stockholders of $4.3 million, wider tha...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder Meetings
Cross Country Healthcare to Be Acquired by Knox Lane
Positive
May 7, 2026
On May 6, 2026, Cross Country Healthcare agreed to be acquired by Knox Lane in an all-cash deal that values the healthcare workforce solutions company at about $437 million, or $13.25 per share, representing a 31% premium to its May 6 close and a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.